CD302 is a transmembrane C-type lectin receptor with diverse biological functions. It mediates endocytosis and phagocytosis while regulating cell adhesion and migration 12. CD302 plays a critical role in guiding dendritic cells to lymph nodes 2 and functions as a restriction factor for hepatitis C virus at the liver cell surface by inhibiting viral entry 34. The protein exists in alternative fusion forms with other transmembrane proteins that alter its function 5. In lung adenocarcinoma, CD302 acts as a tumor suppressor, with low expression correlating with advanced TNM stage and poor prognosis; overexpression inhibits cancer cell proliferation, migration, and invasion 6. CD302 has also emerged as a biomarker across multiple disease contexts: it is associated with peripheral artery disease risk in type 2 diabetes patients 7, validated as a chr2 pain marker through Mendelian randomization 8, elevated in trigeminal neuralgia patients with normalization following surgery 9, and its low expression in multiple myeloma predicts poor overall survival when combined with other CD antigens in a risk score 10. These findings suggest CD302's pleiotropic roles in immune regulation, viral restriction, and malignant disease suppression.